Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Niagen Bioscience (NAGE) Equity Average (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Equity Average for 13 consecutive years, with $73.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Equity Average rose 82.95% to $73.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $73.6 million, a 82.95% increase, with the full-year FY2025 number at $61.3 million, up 64.49% from a year prior.
  • Equity Average was $73.6 million for Q4 2025 at Niagen Bioscience, up from $67.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $73.6 million in Q4 2025 to a low of $20.9 million in Q3 2022.
  • A 5-year average of $36.9 million and a median of $30.0 million in 2021 define the central range for Equity Average.
  • Peak YoY movement for Equity Average: soared 125.48% in 2021, then crashed 46.13% in 2022.
  • Niagen Bioscience's Equity Average stood at $33.6 million in 2021, then fell by 26.02% to $24.8 million in 2022, then grew by 12.21% to $27.9 million in 2023, then skyrocketed by 44.29% to $40.2 million in 2024, then skyrocketed by 82.95% to $73.6 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Equity Average are $73.6 million (Q4 2025), $67.4 million (Q3 2025), and $59.8 million (Q2 2025).